The subsequent presentation was a dose-finding study for Clovis Oncology's CO-1686, a molecule that targets the EGFR T790M mutation in NSCLC patients, and which was recently awarded a 'breakthrough therapy' designation. Designed to target mutant EGFR, CO-1686 does not bind wild-type EGFR, thus increasing specificity and reducing adverse effects, which makes it eligible as first-line therapy in patients with activating EGFR mutations. 3 Clovis wants to develop CO-1686 as an oral treatment for NSCLC patients who have failed EGFR-directed therapy, such as Tarceva (Genentech) or Iressa (AstraZeneca), and have developed the T790M mutation, which is the dominant resistance mechanism to Tarceva/Iressa. 3